BioSpace4h
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...
BioSpace4h
Next-Gen ADCs Driving ‘Renaissance’ in Already Hot Oncology Drug Class
ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...
BioSpace4h
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...
BioSpace1d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
BioSpace2d
Trump’s ‘Team of Self Promoters’ Will Make for Great Reality TV but an Uncertain Biopharma Environment
RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...
BioSpace2d
Merck’s Former Asthma Blockbuster Singulair Could Be Linked to Mental Health Problems: Reuters
A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...
BioSpace2d
AstraZeneca Fends Off Adcomm’s Safety Concerns on Andexxa, Axes Mid-Stage Opioid Use Disorder Drug
The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...
BioSpace2d
FDA Still Undecided About Shortage Status of Lilly’s Tirzepatide
Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...
BioSpace3d
Orion Research Foundation grants EUR 1,109,000 for research in 2025
Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for ...